Analysis of the anti-HIV-1 activity of an anti-p17-derivative peptide (P30-52) monoclonal antibody

Hybridoma

Volumn 18, Issue 4, 1999, Pages 305-314

  Ota, Akemi ^a   Ueda, Shigeharu ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY 8H10; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTIVIRAL ACTIVITY; ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0032726857     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1999.18.305     Document Type: Article

References (22)

1. Ratner L: Genetic organization of HIV. In: Immunology of HIV Infection. Gupta S (Eds.). Plenum Publishing Corp., New York, 1996; pp. 8-9.
2. Levin R, Mhashilkar AM, Dorfman T, Bukovsky A, Zani C, Bagley J, Hinkula J, Niedrig M, Albert J, Wahren B, et al.: Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17. Mol Med 1997;3:96-110.
3. Casella CR, Raffeni LJ, and Panganiban AT: Pleiotropic mutations in the HIV-1 matrix protein that affect diverse steps in replication. Virology 1997;228:294-306.
4. Spearman P, Horton R, Ratner L, and Kuli-Zade I: Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism. J Virol 1997;71:6582-6592.
5. Kiernan RE, Ono A, Englund G, and Freed EO: Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J Virol 1998;72:4115-4126.
6. Liu X, Ota A, Watanabe M, Ueda S, Saitoh A, Shinagawa H, Nakata A, Kurimura T, Wang X, Zhao Y, et al.: Three antigenic regions in p17 of human immunodeficiency virus type 1 (HIV-1) revealed by mouse monoclonal antibodies and human antibodies in HIV-1 carrier sera. Microbiol Immunol 1995;39:775-785.
7. Ota A, Liu X, Fujio H, Sakato N, and Ueda S: random expression of human immunodeficiency virus-1 (HIV-1) p17 (epitopes) on the surface of the HIV-1 infected cell. Hybridoma 1998;17:73-75.
8. Ota A, Tanaka-Taya K, and Ueda S: The cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide. Hybridoma 1999;18:149-157.
9. Burleson FG, Chambers TM, and Wiedbrauk DL: Introduction to quantal virus assays. In: Virology: A laboratory Manual, 1992, Academic Press, Inc., New York, pp. 54-57.
10. Ota A, Bautista AN, Yadav ML, and Ueda S: Anti-P30-52 monoclonal antibody cross-reacted to Env V3 and inhibited the viral multiplication of HIV-1-infected MT-4 cells. Hybridoma 1999; 18:139-147.
11. Ota A, and Ueda S: The inhibitory mechanism of anti-P30-52 monoclonal antibody against human immunodeficiency virus type 1 (HIV-1) multiplication in infected MT-4 cells. Hybridoma 18: 235-241.
12. Srinivas RV, and Hurwitz JL: HIV growth, measurement and neutralization. In: Immunology Methods Manual. Lefkovits I (Ed.). Academic Press, London, England 1995.
13. Rencher SD, Slobod KS, Dawson DH, Lockey TD, and Hurwitz JL: Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals? AIDS Res Hum Retroviruses 1995;11:1131-1133.
14. Lange JMA, Wolf F, Krone WJA, Danner SA, Coutinho RA, and Goudsmit J: Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline. AIDS 1987;1:155-159.
15. Niedrig M, Hinkula J, Weigelt W, L'Age-Stehr J, Pauli G, Rosen J, and Wahren B: Epitope mapping of monoclonal antibodies against Human Immunodeficiency Virus type 1 structural proteins by using peptides. J Virol 1989;63:3525-3528.
16. gag: Identification of epitopes exposed at the surfaces of infected cells. J Virol 1991; 65:4798-4804.
17. Chargelegue D, Colvin BT, and O'Toole CM: A 7-year analysis of anti-gag (p17 and p24) antibodies in HIV-1-seropositive patients with haemophilia: Immunoglobulin G titre and avidity are early predictors of clinical course. AIDS 1993;7(Suppl. 2):S87-90.
18. Chargelegue D, Stanley CM, O'Toole CM, Colvin BT, and Steward MW: The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression. Clin Exp Immunol 1995;99:175-181.
19. Kahn JO, Stites DP, Scillian J, Murcar N, Stryder R, Volberding PV, Naylor PH, Goldstein AL, Sarin PS, Simmon VF, et al.: A phase 1 study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue subunit vaccine in seronegative subjects. AIDS Res Hum Retroviruses 1992;8:1321-1325.
20. Sarin PS, Mora CA, Naylor PH, Markham R, Schwartz D, Kahn J, Haseltine P, Gazzard B, Youle M, Rios A, et al.: HIV-1 p17 synthetic peptide vaccine HGP-30: Induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice. Cell Mol Biol 1995;41:401-407.
21. Zimmerman DH, Ulrich JT, Wright C, Lloyd JP, Winship MD, and Sarin PS: Cross-clade p17 peptide recognition by antisera to HGP-30, a 30 amino acid synthetic peptide antigen from HIV type 1 p17. AIDS Res Hum Retroviruses 1998;14:741-748.
22. Sarin PS, Talmadge JE, Heseltine P, Murcar N, Gendelman HE, Coleman R, Kelsey L, Beckner S, Winship D, and Kahn J: Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice. Vaccine 1999;17:64-71.